Oric Pharmaceuticals
Oric Pharmaceuticals, Inc.
Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that specifically address the challenges of cancer resistance. By focusing on overcoming the biological mechanisms that cause drug resistance in tumors, Oric aims to enhance the effectiveness of existing cancer treatments and improve outcomes for patients.
Products & Team
ORIC-114
ORIC-114 is an orally bioavailable, brain-penetrant, irreversible inhibitor developed to selectively target important genetic mutations such as EGFR exon 20 and HER2 exon 20. This innovative drug candidate is specifically designed for patients with genetically defined cancers who display these mutations.
ORIC-114 addresses the problem of cancer treatment resistance by providing a targeted therapy for patients with specific genetic profiles, potentially improving outcomes for these challenging cases.
The critical challenges include the ineffectiveness of standard therapies for patients who have developed resistance mechanisms, leaving them with limited treatment options.